How to evaluate the therapeutic effect of Ocriplasmin and floaters

Ocriplasmin (Ocriplasmin) is an enzyme preparation used to treat vitreomacular adhesion (VMA) and macular epiretinal membrane (Macular Hole, MH). It helps restore the normal anatomy of the macular area by cutting the adhesion between the vitreous and the macula, thereby improving vision and related symptoms. In recent years, as floaters (i.e., floating black shadows or dot-like images in front of the eyes) have attracted more and more attention from patients, people have gradually increased the evaluation of the application effect of Jetrea in patients with floaters accompanied by VMA.

The occurrence of floaters is mainly related to vitreous liquefaction, posterior vitreous detachment, and slight adhesion between the vitreous and the retina. In some patients, Jetrea may indirectly relieve the floating sensation caused by traction by enzymatically breaking down the adhesion between the vitreous body and the macula. However, it should be noted that Jetrea is not a standard treatment for all floaters. Its main indications are vitreous-macular adhesion and small macular holes. Assessment of treatment efficacy often relies on multimodal fundus imaging, including optical coherence tomography (OCT) and retinal function assessment. OCT can clearly observe the separation of the vitreous body and the macula, the closure of the macular hole, and the changes in the thickness of the macula, which provides an intuitive basis for doctors to judge the effect of treatment.

In clinical evaluations, successful dissociation of the VMAand closure of the macular hole has generally been associated with improved visual function in patients. Some patients experience mild improvement in vision and relief of floaters within a few weeks after Jetrea injection, but the effects vary from individual to individual, and some cases may only achieve anatomical improvement while symptoms continue. When evaluating the treatment effect, doctors will also take into account the patient's vision changes, central retinal thickness and fundus structural reconstruction. In addition, the patient's subjective feelings are also important, such as the reduction of floating objects and the improvement of visual field clarity, which can be used as auxiliary evaluation indicators.

Reference materials:https://www.drugs.com/cdi/ocriplasmin.html